Ignite Creation Date:
2024-05-05 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00038103
Status:
COMPLETED
Last Update Posted:
2010-02-25
First Post:
2002-05-29
Brief Title:
Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
Open-Label Multicentre Controlled Study Of Exemestane Aromasin With Or Without Celecoxib Celebrex In Postmenopausal Women With Advanced Breast Cancer ABC Having Progressed On Tamoxifen
Status:
COMPLETED
Status Verified Date:
2010-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an open-label multicenter randomized 11 randomization ratio study of either exemestane or exemestane plus celecoxib in postmenopausal women with ABC having progressed on tamoxifen
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| A3191139 | None | None | None |